Cancer prevention articles within Nature Medicine

Featured

  • Research Highlight |

    In a head-to-head study, a multitarget version of the widely used FIT (fecal immunochemical test) showed a higher cancer detection rate than the standard test.

    • Karen O’Leary

  • Article
    | Open Access

    A model evaluating cervical screening, triage and treatment strategies to prevent cervical cancer in women living with HIV in Tanzania provides evidence to support the World Health Organization’s recommendation of primary HPV testing starting at age 25 years with 3–5-year regular screening intervals.

    • Michaela T. Hall
    • , Kate T. Simms
    •  & Karen Canfell

  • Brief Communication |

    In a retrospective analysis of patients with Lynch syndrome and primary cancers treated with immune checkpoint inhibitors, 12% developed subsequent malignancies, suggesting that this treatment may not eliminate risk in individuals predisposed to mismatch repair-deficient cancers, and ongoing surveillance is warranted.

    • Emily C. Harrold
    • , Michael B. Foote
    •  & Zsofia K. Stadler

  • Research Highlight |

    Despite a reduction in colorectal cancer incidence, a large, randomized screening study shows no impact of screening on cancer-related deaths.

    • Karen O’Leary

  • Research Highlight |

    A WHO expert panel concluded that a single dose of HPV vaccine has efficacy comparable to that of the two-dose regimen, which could help boost cervical cancer–elimination efforts.

    • Karen O’Leary

  • Letter |

    A new study by Jane Visvader, Geoff Lindeman and colleagues reports on the potential role of RANK signaling in pre-neoplastic breast tissue from BRCA1-mutation carriers and in a mouse model of Brca1-deficient mammary cancer, suggesting that targeting RANK could be explored as an approach to prevent growth of tumors harboring mutated BRCA1.

    • Emma Nolan
    • , François Vaillant
    •  & Geoffrey J Lindeman

  • Letter |

    The authors identify EZH2 as a general underlying dependency of tumors with mutations in the SWI/SNF chromatin regulator complex, and they show that EZH2's pro-tumorigenic role may be dependent on non-catalytic activities. This may pose new opportunities and challenges for using EZH2 as a cancer therapy target.

    • Kimberly H Kim
    • , Woojin Kim
    •  & Charles W M Roberts

  • News & Views |

    Activation of Toll-like receptor (TLR) signaling by microbes in the intestine promotes tumor growth in genetically susceptible mice. Inactivation of extracellular signal–regulated kinase (ERK), a molecule downstream of TLR signaling, may offer a route to preventing colorectal cancer (pages 665–670).

    • Masayuki Fukata
    •  & Maria T Abreu

Browse broader subjects

Browse Cancer prevention across other nature.com journals